Proof of Principle in the Selective Treatment of Cancer by Antibody-Directed Enzyme Prodrug Therapy: The Development of a Highly Potent Prodrug

Perfectly adept for tumor treatment: With the seco‐CBI‐Q galactoside 1 a novel highly potent prodrug for the selective treatment of cancer using the ADEPT approach was developed, which shows very promising results in preclinical trials on a human bronchial carcinoma in SCID mice (see picture; lung t...

Full description

Saved in:
Bibliographic Details
Published in:Angewandte Chemie International Edition 2002-03, Vol.41 (5), p.759-761
Main Authors: Tietze, Lutz F., Feuerstein, Tim, Fecher, Anja, Haunert, Frank, Panknin, Olaf, Borchers, Ulrich, Schuberth, Ingrid, Alves, Frauke
Format: Article
Language:English
Subjects:
ADEPT
Animals
antitumor agents
beta-Galactosidase
Bronchial Neoplasms - drug therapy
Bronchial Neoplasms - pathology
Carcinoma, Pancreatic Ductal - drug therapy
Carcinoma, Pancreatic Ductal - pathology
Cell Division - drug effects
Cyclopropanes - administration & dosage
Cyclopropanes - chemistry
Cyclopropanes - therapeutic use
enzymes
Enzymes - therapeutic use
Female
Galactosides - chemistry
glycosides
Humans
Immunoconjugates - administration & dosage
Immunoconjugates - therapeutic use
Indoles - administration & dosage
Indoles - chemistry
Indoles - therapeutic use
Inhibitory Concentration 50
Male
Mice
Mice, SCID
monoclonal antibodies
Neoplasms - drug therapy
prodrugs
Prodrugs - administration & dosage
Prodrugs - therapeutic use
Prodrugs - toxicity
Tumor Cells, Cultured
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Perfectly adept for tumor treatment: With the seco‐CBI‐Q galactoside 1 a novel highly potent prodrug for the selective treatment of cancer using the ADEPT approach was developed, which shows very promising results in preclinical trials on a human bronchial carcinoma in SCID mice (see picture; lung tissue after (A) and before treatment (B)).
ISSN:1433-7851
1521-3773
DOI:10.1002/1521-3773(20020301)41:5<759::AID-ANIE759>3.0.CO;2-7